Premium
Pharmacokinetics of Single‐Dose Doripenem in Adults With Cystic Fibrosis
Author(s) -
Cirillo Iolanda,
Vaccaro Nicole,
Redman Rebecca,
Black Philip L.,
Kearns Gregory L.
Publication year - 2012
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270011427564
Subject(s) - doripenem , pharmacokinetics , medicine , pharmacology , volume of distribution , cystic fibrosis , meropenem , chemistry , antibiotics , biochemistry , antibiotic resistance
The pharmacokinetics of doripenem and doripenem‐M‐1 (inactive metabolite) were evaluated in an open‐label, 2‐period, single‐sequence study in which single 1‐g and 2‐g doses of doripenem were administered intravenously over 4 hours to adult patients with cystic fibrosis (CF). The systemic exposure to doripenem and doripenem‐M‐1, as measured by observed apparent maximum plasma concentration (C max ) and area under the plasma concentration‐time curve (AUC), increased approximately proportionally to the increase in dose. Other pharmacokinetic parameters of doripenem and doripenem‐M‐1, including clearance, volume of distribution, and elimination half‐life, were similar for the 1‐g and 2‐g doses. The results from this study were also compared with those from a previous study in adult healthy volunteers (HVs) without CF, from a previously conducted pharmacokinetic study, who received single doses of 500 mg and 1 g doripenem administered over 4 hours. The pharmacokinetics of doripenem in adult patients with CF are similar to those from adult HVs, noting some differences in the disposition when comparing body mass index‐adjusted pharmacokinetic parameters.